Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products
Natividad Cuende, Rachele Ciccocioppo, Miguel Forte, et al.
Cytotherapy (2022) Vol. 24, Iss. 7, pp. 686-690
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Expanding access to CAR T cell therapies through local manufacturing
Magdi Elsallab, Marcela V. Maus
Nature Biotechnology (2023) Vol. 41, Iss. 12, pp. 1698-1708
Closed Access | Times Cited: 30
Academic challenges on advanced therapy medicinal products’ development: a regulatory perspective
Eulàlia Olesti, Yoana Nuevo, Mireia Bachiller, et al.
Cytotherapy (2024) Vol. 26, Iss. 3, pp. 221-230
Closed Access | Times Cited: 6
Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)
Fermín Sánchez‐Guijo, Joaquim Vives, Annalisa Ruggeri, et al.
Cytotherapy (2024) Vol. 26, Iss. 7, pp. 681-685
Open Access | Times Cited: 6
Country-specific regulation and international standardization of cell-based therapeutic products derived from pluripotent stem cells
Takamasa Hirai, Satoshi Yasuda, Akihiro Umezawa, et al.
Stem Cell Reports (2023) Vol. 18, Iss. 8, pp. 1573-1591
Open Access | Times Cited: 15
Cell-based medicinal products approved in the European Union: current evidence and perspectives
Stefania Bellino, Anna La Salvia, Maria Francesca Cometa, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products
Laertis Ikonomou, Natividad Cuende, Miguel Forte, et al.
Cytotherapy (2023) Vol. 25, Iss. 9, pp. 920-929
Open Access | Times Cited: 12
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies
Rebecca Gardner, Claire White, Magdi Elsallab, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 8, pp. 776-787
Closed Access | Times Cited: 3
The Current State of Cytotherapy and the Field of Cell and Gene Therapy
William Ying Khee Hwang, Ezzah Mohamed Muzammil
Cytotherapy (2025)
Closed Access
Enhancing the clinical translation of stem cell models by focusing on standardization and international regulatory cooperation
Wei Wang, Anran Song, Hong‐Wen Liu, et al.
World Journal of Stem Cells (2025) Vol. 17, Iss. 4
Closed Access
Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
Sungkyung Lee, Jong Hyuk Lee
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 9
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)
Fermín Sánchez‐Guijo, C. Avendaño, Lina Badimón, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 6, pp. 727-728
Open Access | Times Cited: 9
The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time
Lorenzo Piemonti, Hanne Scholz, Dide de Jongh, et al.
Transplant International (2023) Vol. 36
Open Access | Times Cited: 9
Ethical implications of developing RNA-based therapies for cardiovascular disorders
Mihaela Hostiuc, Alexandru Scafa‐Udriște, Bogdan Iancu, et al.
Frontiers in Bioengineering and Biotechnology (2024) Vol. 12
Open Access | Times Cited: 3
Addressing Risks Derived From the Commodification of Substances of Human Origin: A European Proposal Applicable Worldwide
Natividad Cuende, Anna Vilarrodona, Elena Vuelta, et al.
Transplantation (2023) Vol. 107, Iss. 4, pp. 867-877
Open Access | Times Cited: 8
Regulation of advanced therapies in Europe: Are we on the right track?
Ander Izeta, Natividad Cuende
Cell stem cell (2023) Vol. 30, Iss. 8, pp. 1013-1016
Closed Access | Times Cited: 7
Skin-Derived ABCB5+ Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine
Elke Niebergall‐Roth, Natasha Y. Frank, Christoph Ganss, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 66-66
Open Access | Times Cited: 12
Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape
Костадин Костадинов, Yuliyana Marinova, Kostadin Dimitrov, et al.
Healthcare (2024) Vol. 12, Iss. 4, pp. 458-458
Open Access | Times Cited: 2
The Impact of Umbilical Cord Mesenchymal Stem Cells on Motor Function in Children with Cerebral Palsy: Results of a Real-world, Compassionate use Study
Magdalena Chrościńska-Kawczyk, Izabela Zdolińska-Malinowska, Dariusz Boruczkowski
Stem Cell Reviews and Reports (2024) Vol. 20, Iss. 6, pp. 1636-1649
Closed Access | Times Cited: 2
Impact and challenges of enactment for advanced regenerative medicine in South Korea
Dong‐Sook Kim, SeungJin Bae
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 10
A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe
Joaquim Delgadillo, Erja Kerkelä, Allison Waters, et al.
Cytotherapy (2023) Vol. 25, Iss. 12, pp. 1259-1264
Open Access | Times Cited: 4
Polish regulatory system regarding ATMP hospital exemptions
Jan Pachocki, Frances Verter
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Analysis of global practices in CAR-T cell production organization and an example of implementation at the Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology
E. A. Badrin, Michael Maschan, Dmitry Pershin, et al.
Annals of the Russian academy of medical sciences (2024) Vol. 79, Iss. 6, pp. 507-514
Closed Access | Times Cited: 1
The Evolving Landscape of Potency Assays
Jorge S. Burns
Advances in experimental medicine and biology (2023), pp. 165-189
Closed Access | Times Cited: 3
Unproven cell interventions in Poland and the exploitation of European Union law on advanced therapy medicinal products
Józef Dulak, Marlena Pecyna
Stem Cell Reports (2023) Vol. 18, Iss. 8, pp. 1610-1620
Open Access | Times Cited: 2
Clinical research and drug regulation in the challenging times of individualized therapies: A pivotal role of clinical pharmacology
Antonio Gómez‐Outes, Aránzazu Sancho‐López, Antonio J. Carcas, et al.
Pharmacological Research (2023) Vol. 199, pp. 107045-107045
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top